Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wednesday, August 3 rd
NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales
-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA ® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an exploratory post hoc